Assessment of lipolysis biomarkers in adipose tissue of patients with gastrointestinal cancer.
Cachexia
Cancer
Gene expression, Proteins
Lipolysis
Journal
Cancer & metabolism
ISSN: 2049-3002
Titre abrégé: Cancer Metab
Pays: England
ID NLM: 101607582
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
29
11
2023
accepted:
21
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
Adipose tissue metabolism may be impaired in patients with cancer. In particular, increased lipolysis was described in cancer-promoting adipose tissue atrophy. For this reason, we assessed the expression of the lipolysis-associated genes and proteins in subcutaneous adipose tissue (SAT) of gastrointestinal (GI) cancer patients compared to controls to verify their involvement in cancer, among different types of GI cancers, and in cachexia. We considered patients with GI cancer (gastric, pancreatic, and colorectal) at their first diagnosis, with/without cachexia, and controls with benign diseases. We collected SAT and total RNA was extracted and ATGL, HSL, PPARα, and MCP1 were analyzed by qRT-PCR. Western blot was performed to evaluate CGI-58, PLIN1 and PLIN5. We found higher expression of ATGL and HSL in GI cancer patients with respect to controls (p ≤ 0.008) and a trend of increase for PPARα (p = 0.055). We found an upregulation of ATGL in GI cancer patients with cachexia (p = 0.033) and without cachexia (p = 0.017) vs controls. HSL was higher in patients with cachexia (p = 0.020) and without cachexia (p = 0.021), compared to controls. ATGL was upregulated in gastric cancer vs controls (p = 0.014) and higher HSL was found in gastric (p = 0.008) and in pancreatic cancer (p = 0.033) vs controls. At the protein level, we found higher CGI-58 in cancer vs controls (p = 0.019) and in cachectic vs controls (p = 0.029), as well as in gastric cancer vs controls (p = 0.027). In our cohort of GI cancer patients, we found a modulation in the expression of genes and proteins involved in lipolysis, and differences were interestingly detected according to cancer type.
Sections du résumé
BACKGROUND
BACKGROUND
Adipose tissue metabolism may be impaired in patients with cancer. In particular, increased lipolysis was described in cancer-promoting adipose tissue atrophy. For this reason, we assessed the expression of the lipolysis-associated genes and proteins in subcutaneous adipose tissue (SAT) of gastrointestinal (GI) cancer patients compared to controls to verify their involvement in cancer, among different types of GI cancers, and in cachexia.
METHODS
METHODS
We considered patients with GI cancer (gastric, pancreatic, and colorectal) at their first diagnosis, with/without cachexia, and controls with benign diseases. We collected SAT and total RNA was extracted and ATGL, HSL, PPARα, and MCP1 were analyzed by qRT-PCR. Western blot was performed to evaluate CGI-58, PLIN1 and PLIN5.
RESULTS
RESULTS
We found higher expression of ATGL and HSL in GI cancer patients with respect to controls (p ≤ 0.008) and a trend of increase for PPARα (p = 0.055). We found an upregulation of ATGL in GI cancer patients with cachexia (p = 0.033) and without cachexia (p = 0.017) vs controls. HSL was higher in patients with cachexia (p = 0.020) and without cachexia (p = 0.021), compared to controls. ATGL was upregulated in gastric cancer vs controls (p = 0.014) and higher HSL was found in gastric (p = 0.008) and in pancreatic cancer (p = 0.033) vs controls. At the protein level, we found higher CGI-58 in cancer vs controls (p = 0.019) and in cachectic vs controls (p = 0.029), as well as in gastric cancer vs controls (p = 0.027).
CONCLUSION
CONCLUSIONS
In our cohort of GI cancer patients, we found a modulation in the expression of genes and proteins involved in lipolysis, and differences were interestingly detected according to cancer type.
Identifiants
pubmed: 38167536
doi: 10.1186/s40170-023-00329-9
pii: 10.1186/s40170-023-00329-9
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1Informations de copyright
© 2023. The Author(s).
Références
Al-Sawaf O, Weiss J, Skrzypski M, Lam JM, Karasaki T, Zambrana F, et al. Body composition and lung cancer-associated cachexia in TRACERx. Nat Med. 2023;29:846–58.
doi: 10.1038/s41591-023-02232-8
pubmed: 37045997
pmcid: 7614477
Argilés JM, López-Soriano FJ, Stemmler B, Busquets S. Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management. Nat Rev Clin Oncol. 2023;20:250–64.
doi: 10.1038/s41571-023-00734-5
pubmed: 36806788
Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013;31:1539–47.
doi: 10.1200/JCO.2012.45.2722
pubmed: 23530101
Molfino A, Imbimbo G, Muscaritoli M. Metabolic and histomorphological changes of adipose tissue in cachexia. Curr Opin Clin Nutr Metab Care. 2023;26:235–42.
doi: 10.1097/MCO.0000000000000923
pubmed: 36942899
Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH. Cancer-associated cachexia. Nat Rev Dis Primers. 2018;4:17105.
doi: 10.1038/nrdp.2017.105
pubmed: 29345251
Molfino A, Carletti R, Imbimbo G, Amabile MI, Belli R, di Gioia CRT, et al. Histomorphological and inflammatory changes of white adipose tissue in gastrointestinal cancer patients with and without cachexia. J Cachexia Sarcopenia Muscle. 2022;13:333–42.
doi: 10.1002/jcsm.12893
pubmed: 34939367
Molfino A, Belli R, Imbimbo G, Carletti R, Amabile MI, Tambaro F, et al. Evaluation of Browning Markers in Subcutaneous Adipose Tissue of Newly Diagnosed Gastrointestinal Cancer Patients with and without Cachexia. Cancers (Basel). 2022;14:1948.
doi: 10.3390/cancers14081948
pubmed: 35454855
pmcid: 9025935
Dalal S. Lipid metabolism in cancer cachexia. Ann Palliat Med. 2019;8:13–23.
doi: 10.21037/apm.2018.10.01
pubmed: 30525767
Joshi M, Patel BM. The burning furnace: Alteration in lipid metabolism in cancer-associated cachexia. Mol Cell Biochem. 2022;477:1709–23.
doi: 10.1007/s11010-022-04398-0
pubmed: 35254613
Dahlman I, Mejhert N, Linder K, Agustsson T, Mutch DM, Kulyte A, et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br J Cancer. 2010;102:1541–8.
doi: 10.1038/sj.bjc.6605665
pubmed: 20407445
pmcid: 2869165
Rydén M, Agustsson T, Laurencikiene J, Britton T, Sjölin E, Isaksson B, et al. Lipolysis--not inflammation, cell death, or lipogenesis--is involved in adipose tissue loss in cancer cachexia. Cancer. 2008;113:695–1704.
doi: 10.1002/cncr.23802
Muscaritoli M, Anker SD, Argilés J, Aversa Z, Bauer JM, Biolo G, et al. Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr. 2010;29:154–9.
doi: 10.1016/j.clnu.2009.12.004
pubmed: 20060626
Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011;12:489–95.
doi: 10.1016/S1470-2045(10)70218-7
pubmed: 21296615
Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3:1101–8.
doi: 10.1038/nprot.2008.73
pubmed: 18546601
Yang A, Mottillo EP. Adipocyte lipolysis: from molecular mechanisms of regulation to disease and therapeutics. Biochem J. 2020;477:985–1008.
doi: 10.1042/BCJ20190468
pubmed: 32168372
Das SK, Eder S, Schauer S, Diwoky C, Temmel H, Guertl B, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science. 2011;333:233–8.
doi: 10.1126/science.1198973
pubmed: 21680814
Babic A, Rosenthal MH, Sundaresan TK, Khalaf N, Lee V, Brais LK, et al. Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Nat Commun. 2023;14:4317.
doi: 10.1038/s41467-023-40024-3
pubmed: 37463915
pmcid: 10354105
Muscaritoli M, Lucia S, Farcomeni A, Lorusso V, Saracino V, Barone C, et al. Prevalence of malnutrition in patients at first medical oncology visit: the PreMiO study. Oncotarget. 2017;8:79884–96.
doi: 10.18632/oncotarget.20168
pubmed: 29108370
pmcid: 5668103
Tan Y, Wang M, Yang K, Chi T, Liao Z, Wei P. PPAR-α Modulators as Current and Potential Cancer Treatments. Front Oncol. 2021;11:599995.
doi: 10.3389/fonc.2021.599995
pubmed: 33833983
pmcid: 8021859
Zhao X, Amevor FK, Cui Z, Wan Y, Xue X, Peng C, et al. Steatosis in metabolic diseases: A focus on lipolysis and lipophagy. Biomed Pharmacother. 2023;160:114311.
doi: 10.1016/j.biopha.2023.114311
pubmed: 36764133
Batista ML Jr, Peres SB, McDonald ME, Alcantara PS, Olivan M, Otoch JP, et al. Adipose tissue inflammation and cancer cachexia: possible role of nuclear transcription factors. Cytokine. 2012;57:9–16.
doi: 10.1016/j.cyto.2011.10.008
pubmed: 22099872
Talbert EE, Lewis HL, Farren MR, Ramsey ML, Chakedis JM, Rajasekera P, et al. Circulating monocyte chemoattractant protein-1 (MCP-1) is associated with cachexia in treatment-naïve pancreatic cancer patients. J Cachexia Sarcopenia Muscle. 2018;9:358–68.
doi: 10.1002/jcsm.12251
pubmed: 29316343
pmcid: 5879958
Li Y, Li Z, Ngandiri DA, Llerins Perez M, Wolf A, Wang Y. The Molecular Brakes of Adipose Tissue Lipolysis. Front Physiol. 2022;13:826314.
doi: 10.3389/fphys.2022.826314
pubmed: 35283787
pmcid: 8907745
Nielsen TS, Jessen N, Jørgensen JO, Møller N, Lund S. Dissecting adipose tissue lipolysis: molecular regulation and implications for metabolic disease. J Mol Endocrinol. 2014;52:R199–222.
doi: 10.1530/JME-13-0277
pubmed: 24577718
Laurens C, Bourlier V, Mairal A, Louche K, Badin PM, Mouisel E, et al. Perilipin 5 fine-tunes lipid oxidation to metabolic demand and protects against lipotoxicity in skeletal muscle. Sci Rep. 2016;6:38310.
doi: 10.1038/srep38310
pubmed: 27922115
pmcid: 5138838
Kliewer KL, Ke JY, Tian M, Cole RM, Andridge RR, Belury MA. Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice. Cancer Biol Ther. 2015;16:886–97.
doi: 10.4161/15384047.2014.987075
pubmed: 25457061
Han J, Meng Q, Shen L, Wu G. Interleukin-6 induces fat loss in cancer cachexia by promoting white adipose tissue lipolysis and browning. Lipids Health Dis. 2018;17:14.
doi: 10.1186/s12944-018-0657-0
pubmed: 29338749
pmcid: 5771021
Agustsson T, Rydén M, Hoffstedt J, van Harmelen V, Dicker A, Laurencikiene J, et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007;67:5531–7.
doi: 10.1158/0008-5472.CAN-06-4585
pubmed: 17545636
Fang R, Yan L, Liao Z. Abnormal lipid metabolism in cancer-associated cachexia and potential therapy strategy. Front Oncol. 2023;13:1123567.
doi: 10.3389/fonc.2023.1123567
pubmed: 37205195
pmcid: 10185845
Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, Bozzetti F, et al. ESPEN guidelines on nutrition in cancer patients. Clin Nutr. 2017;36:11–48.
doi: 10.1016/j.clnu.2016.07.015
pubmed: 27637832
Molfino A, Emerenziani S, Tonini G, Santini D, Gigante A, Guarino MPL, et al. Early impairment of food intake in patients newly diagnosed with cancer. Front Nutr. 2023;9:997813.
doi: 10.3389/fnut.2022.997813
pubmed: 36687669
pmcid: 9849803
Muscaritoli M, Imbimbo G, Jager-Wittenaar H, Cederholm T, Rothenberg E, di Girolamo FG, et al. Disease-related malnutrition with inflammation and cachexia. Clin Nutr. 2023;S0261-5614(23):00155–3.
Anderson LJ, Lee J, Anderson B, Lee B, Migula D, Sauer A, et al. Whole-body and adipose tissue metabolic phenotype in cancer patients. J Cachexia Sarcopenia Muscle. 2022;13:1124–33.
doi: 10.1002/jcsm.12918
pubmed: 35088949
pmcid: 8977952